Human pluripotent stem cell-derived macrophages and macrophage-derived exosomes: therapeutic potential in pulmonary fibrosis

Roya Rasaei1†, Apoorvi Tyagi2†, Shima Rasaei3, Seung‑Joon Lee1, Se‑Ran Yang4, Kye‑Seong Kim2, Suresh Ramakrishna2* and Seok‑Ho Hong1,5,6*

Abstract
Pulmonary fibrosis (PF) is a fatal chronic disease characterized by accumulation of extracellular matrix and thickening of the alveolar wall, ultimately leading to respiratory failure. PF is thought to be initiated by the dysfunction and aberrant activation of a variety of cell types in the lung. In particular, several studies have demonstrated that macrophages play a pivotal role in the development and progression of PF through secretion of inflammatory cytokines, growth factors, and chemokines, suggesting that they could be an alternative therapeutic source as well as therapeutic target for PF. In this review, we describe the characteristics, functions, and origins of subsets of macrophages involved in PF and summarize current data on the generation and therapeutic application of macrophages derived from pluripotent stem cells for the treatment of fibrotic diseases. Additionally, we discuss the use of macrophage‑derived exosomes to repair fibrotic lung tissue.

Keywords: Macrophages, IPF, hPSC, Exosomes, Respiratory disease

Introduction
Macrophages are immune cells that originate from progenitors in the bone marrow (BM) that circulate in the peripheral blood and migrate into different tissues [1–4]. Macrophages are the foremost controllers of both innate and acquired immunity and are activated by different endogenous and exogenous signals to mediate immune homeostasis [5]. Macrophages are major mediators of inflammation, tissue repair, and immune function due to their ability to secrete an array of soluble cytokines, chemokines, and growth factors. Specialized macrophages in different tissues are referred to by different names: liver macrophages that promote tissue remodeling and immune responses are called Kupffer cells, macrophages that maintain the immunity of the brain by eliminating dead neurons are referred to as neuronal macrophages or microglia, macrophages that eliminate dysfunctional or old red blood cells (RBCs) are called splenic macrophages, while macrophages that phagocytose dead cells or bacteria in lung tissue are referred to as lung macrophages [6].

Macrophages are abundant in the lung microenvironment and comprise a heterogeneous population of cells with diverse functions and phenotypic plasticity dependent on the inflammatory signals they encounter.
in the lung microenvironment. Lung macrophages are important sentinels that are critical to pulmonary host defenses. Two macrophage populations reside within lungs: alveolar macrophages (AMs) and interstitial macrophages (IMs), which differ in the expression of surface markers as well as their localization and functional phenotype [7, 8]. AMs are primary effector cells that possess both pro-inflammatory and anti-inflammatory properties and express low levels of CD11b and high CD11c levels and colonize the airway space in lungs. By contrast, high CD11b- and CD11c-expressing IMs reside in the lung parenchyma and maintaining immune homeostasis in the respiratory tract [9]. Inflammatory responses of macrophages are associated with the development of acute and chronic pulmonary pathologies including idiopathic pulmonary fibrosis (IPF) [10, 11]. In this review, we describe the characteristics, functions, and origins of subsets of macrophages and discuss the importance and regulation of macrophage polarization in the development of IPF. Additionally, we summarize the current state of knowledge regarding the therapeutic use of pluripotent stem cell-derived macrophages to treat fibrotic diseases and macrophage-derived exosomes to repair fibrotic lung tissue.

**Role of macrophages in lung fibrosis**

**IPF**

IPF is the most common lung disease and is characterized by the progressive deposition of collagen and extracellular matrix, resulting in damaged and scarred lung tissue. The scarring associated with IPF can lead to impaired gas exchange, breathlessness, decreased static lung compliance, and respiratory failure [12–14]. A number of genetic and non-genetic factors contribute to the development of IPF [15]. Non-genetic factors such as cigarette smoking, dust exposure, and infection are believed to increase the risk of IPF [16, 17]. Genetic studies in familial and sporadic IPF patients have revealed an association between IPF susceptibility and telomerase-related genes [18], surfactant-associated genes [19, 20], mucin 5B gene, toll interacting protein (TOLLIP), and the signal peptide peptidase like 2C (SPPL2C) [21, 22]. Additionally, matrix metalloproteinase 1 (MMP1) and matrix metalloproteinase 7 (MMP7) are found in the peripheral blood of individuals with IPF and are highly overexpressed in lung fibrosis and reflect disease progression [23]. The activation of multiple wound-healing pathways is also a characteristic of IPF progression. Necrosis and/or apoptosis of alveolar epithelial cells is a consistent finding in patients with lung fibrosis [24–26]. Macrophages are involved in the wound-healing response in the lung and subsequent IPF development. The involvement of macrophages in IPF is another aspect of lung disease that needs evaluation to understand the role played by these inflammatory cells in the development of IPF.

**Macrophages in IPF**

Although there is a continuum of macrophage polarization beyond the simplified, discrete, in vitro-based classification system, pulmonary macrophages can also be broadly classified into classically activated macrophages (M1 macrophages) and alternatively activated macrophages (M2 macrophages) depending on their functional phenotypes and biological activities [27]. M1 macrophages are induced by lipopolysaccharide (LPS), IFN-γ, and granulocyte–macrophage colony-stimulating factor (GM-CSF) and produce mediators aimed at eliminating foreign materials and debris. The transcription factor interferon regulatory factor 5 (IRF-5) promotes the M1 phenotype during early inflammatory stages to protect against intracellular pathogens by inducing nitric oxide synthase (iNOS) and proinflammatory cytokines such as IL-1b, IL-12b, IL-23, and TNF [28–30]. However, sustained inflammatory responses can trigger fibrotic responses in the lung. By contrast, M2 macrophages, which are induced by IL-4, IL-13, TGF-b, and IL-10 [31], are known to release mediators that downregulate the inflammatory response and promote the resolution of injury and tissue repair. M1 and M2 macrophages have distinct roles in the pathogenesis of pulmonary fibrosis due to their different cytokine expression profiles [10]. Usually, after alveolar epithelial injury, M1 macrophages heal the wound while M2 macrophages are responsible for completing the healing processes or inflammatory responses in the lung [10]. The reaction to unrelenting lung injury is alteration of wound healing process, which ultimately can result in IPF. Lung fibrosis progression has not been successfully halted by previous therapies due to a lack of knowledge of the exact mechanisms by which the balance between M1/M2 macrophage phenotype can be manipulated. Hence, future studies need to focus on the interactions between macrophages and fibroblasts.

**Macrophages derived from pluripotent stem cells**

**Methods to derive macrophages from monocytes and TRMs**

Several advancements have led to the development of different methods to derive generic macrophages, but there are very few methods available for the functional analysis of human M0s. The earliest method for macrophage generation involved direct isolation of tissue resident macrophages (TRMs) from relevant tissues [32–35]; however, insufficient yield and poor cell quality are major limitations of this method [36]. The use of immortalized cell lines from hemato-oncological patients such as THP-1 or U937 cells is a cheap and robust way to
derive resting macrophages (M0s). However, the genetics of these malignant cells limits the application of this approach [37, 38]. Another method widely used for the generation of M0s exploits CD14+ monocytes derived from peripheral blood mononuclear cells. Monocytes are induced by growth factors or cytokines (mainly M-CSF) to generate M0s [39, 40]. An advantage of this method is the ready availability of human peripheral blood samples and the high quantity of monocyte-derived macrophages (MDMs) obtained from individual donors. However, MDMs cannot be used to model TRMs and are unable to proliferate and be maintained under culture conditions for long periods of time [4, 7, 41–44].

**Methods to derive macrophages from PSCs**

Macrophages have also been derived from pluripotent stem cells (PSCs) such as embryonic stem cells (ESCs) and induced human pluripotent stem cells (iPSCs). Most of the methods used follow the common principle of stepwise differentiation of PSCs into M0s through the formation of mesoderm, hemogenic endothelium (HE), hematopoietic progenitors, and monocytic cells, mimicking embryonic hematopoiesis [45–48]. Generation of M0s from PSCs has several advantages over previously established human M0 models. This approach can be used to generate ideal TRM models compared with MDMs due to the easy accessibility and scalability of PSCs. Several protocols have been established to differentiate PSCs into M0s (iMphs), all of which comprise four major stages: (1) mesoderm commitment and HE specification (M/HE stage); (2) endothelial-to-hematopoietic transition and the generation of hematopoietic progenitors (HP stage); (3) myeloid specification and the formation of monocyte-like cells (MY stage); and (4) terminal differentiation of iMphs (MF stage). There are several protocols that differ in the methods used to culture and differentiate PSCs that are outlined below. In 2D-OP9 protocols, PSCs are co-cultured with stromal cells to differentiate into M0s. S17, OP9, C166, UG26, and AM20.1B4 are different types of stromal cells that secrete factors that promote the proliferation of hematopoietic cells [49]. OP9 was successfully used for iMph differentiation due to its ability to prevent early monocyte/M0s bias and differentiation into different types of hematopoietic lineages. Given that OP9 cells are derived from the bone marrow cells of osteopetrosis mice, the use of xenogenic cells limits its therapeutic applications. Stromal cell-independent protocols were developed later and there are three different protocols based on the induction of mesoderm commitment and HE specification (M/HE). Embryoid body (EB)-based three-dimensional (3D) spontaneous protocols (EB-S) generate EBs by culturing PSCs under low-adherent conditions while M/HE differentiation is achieved without the addition of exogenous factors [50–53]. Further, HP and MY differentiation are induced simultaneously by treatment with a combination of cytokines (IL-3 and M-CSF). EB-based 3D factor-assisted protocols (EB-F) involve exposure of EBs to several exogenous factors such as BMP4, SCF, and VEGF to achieve M/HE specification [48, 51]. HP and MY differentiation are induced simultaneously with IL-3 and M-CSF. Some EB-F protocols sequentially differentiate the HP stage into the MY stage. HP differentiation is achieved by treating cells with hematopoietic factors without M-CSF followed by conditional MY differentiation using hematopoietic factors along with M-CSF. EB-independent two-dimensional (2D) factor-assisted protocols (2D-F) rely on culturing PSCs on matrix-coated plates (matrigel) with several external factors (BMP-4, VEGF, SCF, FGF2, CHIR99021, and activin A) for M/HE specification [54–57], followed by sequential differentiation into HP and MY stages. Finally, all protocols involve terminal differentiation from monocyte-like cells to iMphs by cultivating cells in the presence of M-CSF. The schematic representation for the protocols and the detailed information of the exogenous factors supplemented along with the culture medium are discussed in Fig. 1 and Table 1, respectively.

**PSC-derived macrophages as disease models**

Several studies have identified the potential of using PSC-derived macrophages in disease modelling of several diseases. iMph-based disease models are generated mainly through two major approaches. In the first approach, iMphs are generated using patient-derived iPSCs. This method has been used to model Gaucher disease, familial Mediterranean fever, Alzheimer disease, Tangier disease, chronic granulomatous disease (CGD), and Parkinson’s disease [58–62]. In the second approach, iMphs are generated using healthy donors-derived iPSCs mutated to carry the disease-associated mutations. This method has been successfully used to model CGD [63] and very-early onset bowel disease (VEOBD) [64, 65].

PSC-derived macrophages have also been used as a standard model to study macrophage-pathogen interactions and determine the role of human genetics in disease outcomes. Two closely related mosquito-transmitted flaviviruses (Zika virus and Dengue virus) have been studied using iMphs [66]. PSC-derived macrophages are highly relevant to study infectious agents that require macrophages as a source of persistence and replication, such as Chlamydia [67], Salmonella [68], and HIV [69]. These studies suggest that M0s models can therefore be utilized to determine the impact of infectious agents on disease pathogenesis and persistence.
Recent emergence of three-dimensional (3D) model systems, such as organoids and spheroids, and hydrogel systems have advanced our understanding of the tissue microenvironment better than two-dimensional (2D) models. The intact 3D structure allows replication of cell–cell and cell–matrix interactions to study regenerative medicine, disease modelling, and drug development in a variety of diseases. In this review, we outline the
current 3D models to elucidate cellular and molecular cues in IPF and drug discovery.

**3D models of IPF and drug discovery**
Despite significant research, the development of effective therapies for IPF faces challenges due to the lack of in vitro models to mimic disease pathophysiology. Lung 3D cultures including precision cut lung slices (PCLS), hydrogels, and lung organoids have emerged as valuable tools for drug discovery and testing in a variety of pulmonary diseases including IPF [70–73]. PCLS maintain the native lung environment and is a relevant in vitro model to study lung fibrosis and drug testing in a diseased tissue condition [74]. Hydrogels are water-swollen cross-linked networks of polymers and offer another in vitro model to study IPF. Hydrogels can be customized to model normal or diseased microenvironments by altering biomaterials and crosslinking mechanisms [73]. The generation of lung

---

**Table 1** Culture medium and exogenous factors supplied during iPSCs differentiation into iMphs

| Protocol      | Stage | Exogenous differentiation factors | Medium                |
|---------------|-------|-----------------------------------|-----------------------|
| EB-S          | PSC expansion | FGF2                              | KO-DMEM, DMEM/F12, AdvDMEM |
|               | Stage 1     | NA                                | KO-DMEM, DMEM/F12, AdvDMEM |
|               | Stage 2 and 3 | IL3 + M-CSF                        | X-VIVO 15, X-VIVO 15 RPMI |
|               | Stage 4     | M-CSF                              | X-VIVO 15 RPMI         |
| EB-F HP + MY  | PSC expansion | FGF2                              | mTeSR1, DMEM/F12, AdvDMEM |
|               | Stage 1     | BMP4/VEGF/SCF                      | mTeSR1, DMEM/F12, AdvDMEM |
|               | Stage 2 and 3 | IL3 + M-CSF                        | X-VIVO 15, X-VIVO 15 + RPMI |
|               | Stage 4     | M-CSF                              | X-VIVO 15 RPMI         |
| EB-F HP → MY  | PSC expansion | FGF2                              | DMEM/F12              |
|               | Stage 1     | BMP4/VEGF/SCF/FGF2/Flt3L/CHIR/ActA | StemPro-34, mTeSR1, KO-DMEM |
|               | Stage 2     | VEGF/SCF/FGF2/Flt3L/IL3-M-CSF      | StemPro-34, DMEM/F12, AdvDMEM |
|               | Stage 3     | VEGF/SCF/FGF2/Flt3L/IL3/M-CSF/GM-CS| StemPro-34, DMEM/F12, AdvDMEM |
|               | Stage 4     | M-CSF                              | RPMI                  |
| 2D-F          | PSC expansion | NA                                | mTeSR1, E8, TeSR-E8   |
|               | Stage 1     | BMP4/VEGF/FGF2/CHIR/ActA/S G/SCF   | StemPro-34, mTeSR1, E8, IMDM/F12 |
|               | Stage 2     | VEGF/FGF2/SCF/TPO/Flt3/IL3/IL6    | StemPro-34, IMDM/F12 (DMEM/F12) |
|               | Stage 3     | FGF2/SCF/Flt3/IL3/IL6/CSF         | StemPro-34, IMDM/F12 (DMEM/F12) |
|               | Stage 4     | M-CSF                              | RPMI                  |
organoids using hPSCs is a recent method to study the development of fibrosis and to screen novel drugs. hPSC-derived lung organoid models retain patient gene mutations and allow an improved understanding of molecular mechanisms of fibrosis. Strikoudis et al. demonstrate the importance of hPSC-derived lung organoids to model fibrotic lung disease wherein they identified the therapeutic potential of interleukin-11 (IL-11) in lung fibrosis [75]. Korogi et al. also provide insight into the potential role of hPSC-derived lung organoids in disease modeling [76]. Cystic fibrosis patient-specific iPSC-derived lung epithelial cells have been used as an in vitro model to test novel small-molecule compounds called cystic fibrosis correctors [77]. The therapeutic value of NP-011 in assessing the anti-fibrotic potential of milk fat globule-EGF factor 8 (MFG-E8) protein has been demonstrated by hPSC-derived multicellular alveolar organoids containing functional alveolar epithelial and mesenchymal cells as an in vitro model for pulmonary fibrosis [70]. hPSC-based alveolar organoids also served as a relevant model in vitro to evaluate the toxic effect of particulate matter (PM2.5) on fetal alveolar development and acute respiratory syndrome coronavirus 2 (SARS-CoV-2) susceptibility [78].

A major drawback of these organoids is lack of immune cell components, such as macrophages, which limits the recapitulation of in vivo cellular physiology to model IPF and design subsequent drug screening approaches. Multicellular alveolar organoids with macrophages (MacAOs) exhibit phenotypic and functional resemblance to human macrophages and can demonstrate critical pulmonary fibrosis pathological features such as inflammation, collagen accumulation.

**Macrophage-derived extracellular vesicles**

Macrophages are blood immune cells that reside in all tissues and constitute the first line of defense against invading pathogens. Any abnormality in macrophage responses may result in uncontrolled inflammation and immune disorders, which are implicated in many diseases including renal inflammation and fibrosis [79]. Activated macrophages communicate with target cells via direct cell-to-cell contact and/or release of cytokines and extracellular vesicles (EVs) to exert their immunomodulatory functions. EVs are membrane-enclosed vesicles that can be classified as large oncosomes (LOs, ~1–10 μm), apoptotic bodies (ABs, ~1–5 μm), microvesicles (MVs, ~200–1000 nm), exosomes (Exos, ~30–200 nm), or exomeres (<50 nm) on the basis of their size [80]. EVs exhibit similar properties to their parent cells and function as vital carriers to transfer cargo such as proteins, nucleic acids, and metabolites from parent cells to recipient cells. The role of macrophage-derived EVs, especially exosomes, has been widely investigated in different diseases to determine the roles played by EVs in disease progression. In this review, we primarily focus on the roles of macrophage-derived exosomes in disease and therapy (Fig. 2).

Exosomes are cell-secreted, nanosized, bi-lipid vesicles continuously secreted from various types of cells including alveolar epithelial cells, fibroblasts, and inflammatory cells [81]. Exosomes contribute to biological processes by transporting various bioactive molecules, such as nucleic acids (including miRNAs), proteins, and lipids [82–87]. Exosomes regulate various inflammatory and angiogenic pathways by transferring miRNAs from a donor to a recipient cell [83, 88–90]. Exosomes are considered to promote the polarization of macrophages [91, 92]. A large proportion of microvesicles in the blood are derived from macrophage-derived exosomes [93]. Exosomal-enclosed miRNAs have been shown to play crucial roles in inflammation, tissue repair, and fibrogenesis [94]. MicroRNAs are small non-coding single-stranded RNAs containing 18–25 nucleotides that are widely distributed in various organisms from viruses to humans [95]. To date, more than 1000 human miRNAs have been found. These molecules act as regulators of gene expression by inhibiting protein translation, and play key roles in signal transduction, tissue and organ development, and other biological processes [96, 97]. Previous studies have demonstrated that exosomes play a pivotal role in various pulmonary diseases such as IPF, chronic obstructive pulmonary disease (COPD), and asthma [98–100].

**COPD**

COPD is a chronic inflammatory lung disease caused by significant exposure to noxious particles or gases and is characterized by obstructive airflow resulting in breathing abnormalities. The symptoms of COPD are further exacerbated by several environmental factors such as smoking. Bronchial epithelial cells (BECs), the primary cells in contact with external stimuli such as cigarette smoke, play a critical role in airway homeostasis and are considered to be major EVs producer in the lung. Elevated levels of exosomes have been found to correlate with C-reactive protein (CRP), soluble tumor necrosis factor receptor-1 (sTNFR1), and interleukin (IL)-6 levels; all these molecules are plasma biomarkers of systemic inflammation with a potential pathophysiological role in COPD [101]. Exosomes secreted in COPD patients contain miRNAs (miR-210) that promote inflammation and alter the gene expression of target cells. Moreover, miRNAs from plasma-derived vesicles can serve as biomarkers in smokers and COPD patients [102].
Asthma
Asthma is a common lung disease that affects both children and adults and that causes recurrent episodes of wheezing, breathlessness, and chest tightness [103]. Cells such as bronchial epithelial cells, dendritic cells, eosinophils, mast cells, and T-cells release cytokines in this disease [104–106]. Eosinophil-derived exosomes activate structural lung cells and contribute to the pathogenesis of asthma [107]. Levels of serum exosomes containing miRNA-125b have been found to be higher in patients with asthma and may serve as a marker of asthma severity [108]. Studies in mice have revealed a protective role for M2 macrophage-derived exosomes. Under asthmatic conditions induced by ovalbumin, miR-370 levels were found to be reduced in M2 macrophage-derived exosomes and were found to be correlated with improved OVA-induced lung fibrosis and inflammatory responses [91].

IPF
IPF is a chronic, progressive, and idiopathic interstitial pneumonia characterized by the replacement of healthy tissue by altered extracellular matrix and an impaired alveolar structure. Therapy for IPF focuses mainly on
prolonging the life expectancy of patients by slowing down disease progression [109, 110]. For this reason, new pharmacological treatments and biomarkers to ensure better outcomes and diagnose patients early are needed. A recent study investigated the quantity of microRNAs in serum extracellular vesicles, including exosomes, of mice with bleomycin-induced lung fibrosis, and reported significant up-regulation of serum EV miR-21e5p in both the acute and chronic fibrotic phases. Furthermore, as miR-21e5p promotes TGF-b signaling, which is a key signaling pathway in IPF, miR-21e5p was suggested to be a potential biomarker of IPF [111]. EVs were also found to promote the proliferation and activation of fibroblasts in lungs and participate in the pathogenesis of IPF by mediating WNT5A signaling [112]. In another study, two types of miRNAs were found to be associated with IPF: (1) sputum macrophages were found to contain elevated levels of exosomal miR-142-3p in IPF while (2) macrophage-derived exosomes exerted a protective effect against pulmonary fibrosis progression via the delivery of antifibrotic miR-142-3p [83].

**Therapeutic potential of exosomes in chronic respiratory diseases**

The therapeutic potential of exosomes extends to many diseases, including those of the lung, liver, kidney, and heart. Exosomes have been widely studied by several pharmaceutical companies to create products with therapeutic applications. MSC-derived exosomes developed by Aegle Therapeutics are under phase 1/2 clinical trials for dermalological disorders (NCT04173650). Another company, Carmine Therapeutics, derived EVs from RBCs to develop next-generation gene therapies to overcome the limitations of existing viral-based therapies such as low transgene capacity, immunogenicity, and other manufacturing challenges.

Exosome-based therapy is currently also being pursued in lung diseases such as IPF, COPD, acute lung injury (ALI), acute respiratory distress syndrome (ARDS), and bronchopulmonary dysplasia (BPD). MSC-derived exosomes have been used to treat ARDS [113] and protect against cigarette smoke-induced damage [114]. Intrasal delivery of exosomes derived from human amnion epithelial cells (hAECs) targets inflammatory and regenerative cascades of IPF to reverse lung fibrosis and enhance endogenous lung repair [115]. Similarly, inhalation of lung spheroid cell-secretomes (LSC-Sec) and exosomes (LSC-Exo) has been shown to be beneficial in treating lung fibrosis by reversing alveolar damage and decreasing myofibroblast proliferation and collagen accumulation [116]. Endothelial progenitor cell (EPC)-derived exosomes containing miR-126 attenuated LPS-induced ALI/ARDS and restored pulmonary integrity in a rat model of lung injury [117]. A mouse model study of hypoxia-induced pulmonary hypertension revealed that the cyto-protective role of MSCs in the lung is mediated by exosomes [118]. Exosomes have also been used to treat neonatal lung diseases. Treatment of a neonatal mouse model of hyperoxia-induced BPD with MSC-exosomes significantly improved lung morphology and associated pulmonary fibrosis [119]. Blood plasma-derived exosomes for early diagnosis of lung cancer (NCT04529915) and exosome-based identification of malignant and benign pulmonary nodules (NCT04182893) are currently being investigated in clinical trials. However, more research is needed to explore the therapeutic potential and niche of exosomes.

**Conclusions**

Macrophages are critical players in maintaining homeostasis and immune responses to the external environment. Different types of macrophages secrete various pro-inflammatory and anti-inflammatory signals and affect several processes ranging from immune protection to wound healing [120–127]. The pro-inflammatory and anti-inflammatory functions of macrophages depend on the cellular microenvironment, which enables fine-tuning of the transcriptomic and functional response according to homeostatic needs. Any dysregulation in this balance can lead to inflammation, cancer initiation, cardiovascular disorders, and development of fibrosis. Thus, macrophages are potential therapeutic targets in various disorders; however, the lack of efficient models to replicate macrophages has limited their therapeutic value.

The groundbreaking discovery by Takahashi and Yamanaka of stem cells has led to their use to model disease progression, test drugs, and design individual-specific treatments. PSC-derived macrophages have become a highly attractive source for cell and gene therapy. The iMph approach has been successful used to correct genetic mutations and improve phagocyte functions in CGD and VEOBD [64, 65]. The development of novel therapeutic targets for diseases involving macrophages such as pulmonary alveolar proteinosis and liver fibrosis further expands the therapeutic applications of PSC-derived macrophages. Pulmonary transplantation of gene-edited host macrophages into a murine model of hereditary pulmonary alveolar proteinosis had beneficial therapeutic effects [128]. Transplantation of human iPSC-derived macrophages upon intrapulmonary development into AM-like cells resulted in a striking reduction of alveolar protein and surfactant D deposition and attenuated the hereditary pulmonary alveolar proteinosis (herPAP) phenotype [129]. TALEN-mediated integration of the corrected gene granulocyte–macrophage
colony-stimulating factor receptor alpha-chain (CD116) into patient-specific iPSCs resulted in functionally compatible macrophages [130]. Intratracheal injection of human iPMPs in an acute *P. aeruginosa* infection model enhanced pulmonary immunity [50]. Therapeutic application of macrophages significantly reduced the amount of hepatic fibrosis in a model of liver injury [131]. Further, the identification of an active compound against *M. tuberculosis* using iPMPs to screen a 3,716-compound library expanded the therapeutic uses for PSC-derived macrophages as drug testing models [132]. Together, these studies suggest that PSC-derived macrophages are promising biomaterials for the treatment of several diseases (Fig. 2).

EVs derived from macrophages have become widely accepted as disease biomarkers and therapeutic tools. For example, the presence of immune molecules on the surface of EVs [133] and elimination of macrophage-associated risks such as cytokine release syndrome [134] have highlighted the potential of macrophage-derived EVs in therapeutics. Future research should focus on establishing efficient protocols to generate economically feasible, high-yield, clinically-applicable generic macrophages. Elucidating the specific roles of lung macrophages in fibrotic lung disorders would facilitate the development of effective macrophage-based therapeutics.

**Abbreviations**
Pulmonary fibrosis; hPSC: Human pluripotent stem cells; RBCs: Red blood cells; AMs: Alveolar macrophages; IMs: Interstitial macrophages; TOLLIP: Toll-interacting protein; MMP: Matrix metalloproteinase; LPS: Lipopolysaccharide; GM-CSF: Granulocyte-macrophage colony-stimulating factor; IRF-5: Interferon regulatory factor 5; TRMs: Tissue resident macrophages; M0s: Resting macrophages; MDMs: Monocyte-derived macrophages; EB: Embryoid body; VEOMD: Very-early onset bowel disease; PCLS: Precision cut lung slices; MFG-E8: Milk fat globule-EGF factor 8; EVs: Extracellular vesicles; COPD: Chonic obstructive pulmonary disease; BECs: Bronchial epithelial cells; CRP: C-reactive protein; sTNFR1: Soluble tumor necrosis factor receptor-1; ALI: Acute lung injury; ARDS: Acute respiratory distress syndrome; BPD: Bronchopulmonary dysplasia; hAECs: Human amnion epithelial cells; herPAP: Hereditary pulmonary alveolar proteinosis.

**Acknowledgements**
We like to thank all members of SHH and SR lab for their help and support in reviewing the manuscript.

**Author contributions**
SHH and SR supervised the overall process and wrote the manuscript. The main draft of the manuscript was written by RR and AT. Revised by SR, SJL, SRY and KSK. AT, SHH and SR constructed the figures and tables. All authors discussed the related studies and approved the final manuscript.

**Funding**
This research was supported by a grant from the Korea Fund for Regenerative Medicine (KFRM) funded by the Korean government (the Ministry of Science and ICT, the Ministry of Health & Welfare) (22A0034L1-01) as well as the Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Korean government (MSIT) (2022M3A9E4016936, 2022M3A9E4082648 and 2019R1A2C2005453). Finally, this study was funded in part by the ‘Experts Training Graduate Program for Particulate Matter Management’, a program of the Ministry of the Environment, Korea.

**Availability of data and materials**
Not applicable.

**Code availability**
Not applicable.

**Declarations**

**Ethics approval and consent to participate**
Not applicable.

**Consent to participate**
Not applicable.

**Consent for publication**
Not applicable.

**Competing interests**
The authors declare no conflict of interest.

**Author details**
1. Department of Internal Medicine, School of Medicine, Kangwon National University, 2 Kangwondaehakgil, Chuncheon, Gangwon-do 24431, South Korea. 2. Graduate School of Biomedical Science and Engineering, Hanyang University, Seoul 04763, South Korea. 3. Department of Cellular and Molecular Science, Falavarjan Branch, Islamic Azad University, Falavarjan, Iran. 4. Department of Thoracic and Cardiology, School of Medicine, Kangwon National University, Chuncheon 24341, South Korea. 5. Institute of Medical Science, Kangwon National University, Chuncheon 24341, South Korea. 6. KW-Bio Co., Ltd, Wonju, South Korea.

**Received:** 16 July 2022  **Accepted:** 14 August 2022

**Published online:** 02 September 2022

**References**

1. Saha S, Shalova IN, Biswas SK. Metabolic regulation of macrophage phenotype and function. Immunol Rev. 2017;280(1):102–11.

2. Epelman S, Lavine KJ, Randolph GJ. Origin and functions of tissue macrophages. Immunity. 2014;41(1):21–35.

3. Guilliams M, Ginhoux F, Jakubzick C, Naik SH, Onai N, Schraml BU, et al. Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny. Nat Rev Immunol. 2014;14(8):S71–8.

4. Yona S, Kim KW, Wolf Y, Mildner A, Varol D, Breker M, et al. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. Immunity. 2013;38(1):79–91.

5. Schirmer M, Garner A, Vlamakis H, Xavier RJ. Microbial genes and pathways in inflammatory bowel disease. Nat Rev Microbiol. 2019;17(8):497–511.

6. Gordon S, Pludermann A. Tissue macrophages: heterogeneity and functions. BMC Biol. 2017;15(1):53.

7. Guilliams M, De Kleer I, Henri S, Post S, Vanhoutte L, De Prijck S, et al. Alveolar macrophages develop from fetal monocytes that differentiate into long-lived cells in the first week of life via GM-CSF. J Exp Med. 2013;210(10):1977–92.

8. Bedoret D, Wallemacq H, Marichal T, Desmet C, Quesada Calvo F, Henry E, et al. Lung interstitial macrophages alter dendritic cell functions to prevent airway allergy in mice. J Clin Invest. 2009;119(12):3723–38.

9. Byrne AJ, Mathie SA, Gregory LG, Lloyd CM. Pulmonary macrophages: key players in the innate defence of the airways. Thorax. 2015;70(12):1189–96.

10. Zhang L, Wang Y, Wu G, Xiong W, Gu W, Wang CY. Macrophages: friend or foe in idiopathic pulmonary fibrosis? Respir Res. 2018;19(1):170.

11. Byrne AJ, Maher TM, Lloyd CM. Pulmonary macrophages: a new therapeutic pathway in fibrosing lung disease? Trends Mol Med. 2016;22(4):303–16.

12. Lederer DJ, Martinez FJ. Idiopathic pulmonary fibrosis. N Engl J Med. 2018;378(19):1811–23.
13. Helling BA, Yang IV. Epigenetics in lung fibrosis: from pathobiology to treatment perspective. Curr Opin Pulm Med. 2015;21(5):454–62.
14. Wilson MS, Wynn TA. Pulmonary fibrosis: pathogenesis, etiology and regulation. Mucosal Immunol. 2009;2(2):103–21.
15. Evans CM, Fingerlin TE, Schwartz MI, Lynch D, Kuche J, Warg L, et al. A genetic disease that involves mucociliary dysfunction of the peripheral airways. Physiol Rev. 2016;96(4):1567–91.
16. Folcik VA, Garofalo M, Coleman J, Donegan JJ, Rabbani E, Suster S, et al. Idiopathic pulmonary fibrosis is strongly associated with productive infection by herpesvirus saimiri. Mod Pathol. 2014;27(6):851–62.
17. Garcia-Sanchez A, Buendia-Roldan J, Fernandez-Plata MR, Navarro C, Perez-Padilla R, Vargas MH, et al. Familial pulmonary fibrosis is the strongest risk factor for idiopathic pulmonary fibrosis. Respir Med. 2011;105(12):1902–7.
18. de Diaz LA, Cronkhite JT, Katzenstein AL, Godwin JD, Ragu G, Glazer CS, et al. Telomere lengths, pulmonary fibrosis and telomerase (TERT) mutations. PLoS One. 2010;5(5):e10680.
19. Wang Y, Kuan PJ, Xing C, Cronkhite JT, Torres F, Rosenblatt RL, et al. Familial pulmonary fibrosis and lung cancer. Am J Hum Genet. 2009;84(1):52–9.
20. Lawson WE, Grant SW, Ambrosini V, Donegan JJ, Rabbani E, Suster S, et al. Genetic defects in surfactant protein A2 are associated with pulmonary fibrosis and lung cancer. Am J Pathol. 2007;171(4):1257–65.
21. Rosás IO, Richards TJ, Konishi K, Zhang Y, Gibson K, Lokshin AE, et al. MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med. 2008;5(4):e93.
22. Kuhn C, McDonald JA. The roles of the myofibroblast in idiopathic pulmonary fibrosis. Ultrastructural and immunohistochemical features of sites of active extracellular matrix synthesis. Am J Pathol. 1991;138(5):1257–65.
23. Kuhn C 3rd, Boldt J, King TE Jr, Crouch E, Vartio T, McDonald JA. An immunohistochemical study of architectural remodeling and connective tissue synthesis in pulmonary fibrosis. Am Rev Respir Dis. 1989;140(6):1693–703.
24. Myers JL, Katzenstein AL. Epithelial necrosis and alveolar collapse in the pathogenesis of usual interstitial pneumonia. Chest. 1988;94(6):1309–11.
25. Locati M, Mantovani A, Sica A. Macrophage activation and polarization as an adaptive component of innate immunity. Adv Immunol. 2013;120:163–84.
26. Saradha A, Do DC, Kumar S, Fu QL, Gao P. Macrophage polarization and allergic asthma. Transl Res. 2018;191:1–14.
27. Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goedert S, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity. 2014;41(1):14–20.
28. Murray PJ, Wynn TA. Obstacles and opportunities for understanding macrophage polarization. J Leukoc Biol. 2011;89(4):557–63.
29. Zhong B, Yang X, Sun Q, Liu L, Lan X, Tian J, et al. Pdcd4 modulates cell–cell adhesion and alternative activation in monocytes. J Immunol. 2019;11;11:1065–75.
30. Vijayan V, Pradhan P, Braud L, Fuchs HR, Guerler F, Motterlini R, et al. Human and murine macrophages exhibit differential metabolic responses to lipopolysaccharide—a divergent role for glycolysis. Redox Biol. 2019;22:101477.
31. Schneemann M, Schoeden G. Macrophage biology and immunology: man is not a mouse. J Leukoc Biol. 2007;81(3):579 (discussion 580).
32. Albina JE, Reichner JS. Detection of reactive oxygen intermediate production by macrophages. Methods Mol Med. 2003;78:369–76.
33. Weinberg JB. Nitric oxide production and nitric oxide synthase type 2 expression by human mononuclear phagocytes: a review. Mol Med. 1998;4(9):557–91.
34. Summers KM, Bush SJ, Hume DA. Network analysis of transcriptomic diversity amongst resident tissue macrophages and dendritic cells in the mouse mononuclear phagocyte system. PLoS Biol. 2020;18(10):e3000859.
35. Rodebell KB, Koch PD, Weissleder R. Screening for new macrophage therapeutics. Theranostics. 2019;9(25):7714–29.
36. Bosshart H, Heinzelmann M. THP-1 cells as a model for human monocytes. Ann Transl Med. 2016;4(21):438.
37. Pleasner A. Increasing the yield of human mononuclear cells and low serum conditions for in vitro generation of macrophages with M-CSF. J Immunol Methods. 2003;279(1–2):287–95.
38. Brugger W, Kreutz M, Andresen R. Macrophage colony-stimulating factor is required for human monocyte survival and acts as a cofactor for their terminal differentiation to macrophages in vitro. J Leukoc Biol. 1991;49(5):483–8.
39. Hoeffel G, Chen J, Lavin Y, Low D, Almeida FF, See P, et al. C-Myb(+)-erythro--myeloid progenitor-derived fetal monocytes give rise to adult tissue-resident macrophages. Immunity. 2015;42(4):665–78.
40. Hashimoto D, Chow A, Norizat C, Teo P, Beasley MB, Leboeuf M, et al. Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating adult monocytes. Immunity. 2013;38(4):792–804.
41. Schulz C, Gomez Perdiguero E, Chorro L, Szabo-Rogers H, Cagnard N, Kierdorf K, et al. A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science. 2012;336(6077):86–90.
42. Gao J, Ginhoux F, Greter M, Leboeuf M, Nandi S, See P, Gokhan S, et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science. 2010;330(6005):841–5.
43. Tasnim F, Xing J, Huang X, Mo S, Wei X, Tan MH. Generation of mature kuffer cells from human induced pluripotent stem cells. Biomaterials. 2019;192:377–91.
44. Lee CZW, Kozaki T, Ginhoux F. Studying tissue macrophages in vitro: are iPS‑C‑derived cells the answer? Nat Rev Immunol. 2018;18(11):716–25.
45. Takata K, Kozaki T, Lee CZW, Thion MS, Otsuka M, Lim S, et al. Induced pluripotent-stem-cell-derived primitive macrophages provide a platform for modeling tissue-resident macrophage differentiation and function. Immunity. 2017;47(1):183–198 e186.
46. Buchrieser J, James W, Moore MD. Human induced pluripotent stem cell-derived macrophages share ontology with Myb-independent tissue-resident macrophages. Stem Cell Reports. 2017;8(2):334–45.
47. Vodyanik MA, Bork JA, Thomson JA, Sukliivi H. Human embryonic stem cell-derived CD34+ cells: efficient production in the coculture with OP9 stromal cells and analysis of lymphohematopoietic potential. Blood. 2005;105(2):617–26.
48. Ackermann M, Kempf H, Hetzel M, Hesse C, Hashchtn AR, Brickert K, et al. Bioreactor-based mass production of human iPSC-derived macrophages enables immunotherapies against bacterial airway infections. Nat Commun. 2018;9(1):5088.
49. van Wilgenburg B, Brownie C, Vowles J, Cowley SA. Efficient, long term production of monocyte-derived macrophages from human pluripotent stem cells under partly-defined and fully-defined conditions. PLoS ONE. 2013;8(8):e71998.
50. Panicker LM, Miller D, Park TS, Patel B, Azevedo JL, Awad Q, et al. Induced pluripotent stem cell model recapitulates pathologic hallmarks of Gaucher disease. Proc Natl Acad Sci U S A. 2012;109(48):18054–9.
51. Itskovitz-Eldor J, Schuldiner M, Karsenti D, Eden A, Yanuka O, Aitm M, et al. Differentiation of human embryonic stem cells into embryoid bodies compromising the three embryonic germ layers. Mol Med. 2000;6(2):88–95.
52. Kontinen H, Cabral-da-Silva ME, Ostensson S, Wojciechowski S, Shakinzyanova A, Caligola S, et al. PSEN1 DeltaE9, APPSwe, and APOE4 confer disparate phenotypes in human iPS–derived microglia. Stem Cell Rep. 2019;13(4):669–83.
53. Cao X, Yakala GK, van den Hil FE, Cochane A, Mummery CL, Orlova VW. Differentiation and functional comparison of monocytes and macrophages from hiPSCs with peripheral blood derivatives. Stem Cell Rep. 2019;12(6):1282–97.
54. Takada S, Kambe N, Kawasaki Y, Niwa A, Honda-Ozaki F, Kobayashi K, et al. Pluripotent stem cell models of Blau syndrome reveal an iN gamma-dependent inflammatory response in macrophages. J Allergy Clin Immunol. 2018;141(1):339–43 e311.
55. Yanagimachi MD, Niwa A, Tanaka T, Honda-Ozaki F, Nishimoto S, Murata Y, et al. Robust and highly-efficient differentiation of functional...
monocytic cells from human pluripotent stem cells under serum- and feeder cell-free conditions. PLoS ONE. 2013;8(4):e59243.

58. Shiba T, Tanaka T, Ida H, Watanabe M, Nakaseko M, Otsawa M, et al. Functional evaluation of the pathological significance of MEVF variants using induced pluripotent stem cell-derived macrophages. J Allergy Clin Immunol. 2019;144(5):1438-1441 e1412.

59. Brownjohn PW, Smith J, Solanki R, Lohmann H, Houlden H, Hardy J, et al. Functional studies of missense TREM2 mutations in human stem cell-derived microglia. Stem Cell Rep. 2018;10(4):1294–304.

60. Haenseler W, Zambon F, Lee H, Vowles J, Rinaldi F, Duggal G, et al. Excess inflammatory cytokines compromise phagocytosis in iPSC-derived macrophages. Sci Rep. 2017;7(1):9003.

61. Aflaki E, Borger DK, Moaven N, Stubblefield BK, Rogers SA, Patnaik J, et al. Targeted Sens J, Hoffmann D, Lange L, Vollmer Barbosa P, Morgan M, Falk CS, et al. Human pluripotent stem-derived microglia. Stem Cell Rep. 2018;10(4):1294–307.

62. Klatt D, Cheng E, Philipp F, Selich A, Dahlke J, Schmidt RE, et al. Targeted Sens J, Hoffmann D, Lange L, Vollmer Barbosa P, Morgan M, Falk CS, et al. Human pluripotent stem-derived microglia. Stem Cell Rep. 2018;10(4):1294–307.

63. Kim JH, An GH, Kim JY, Rasaei R, Kim WJ, Jin X, et al. Directed differentiation of human pluripotent stem cells into mature airway epithelia expressing functional CFTR protein. Nat Biotechnol. 2012;30(9):876–82.

64. Kunz H, Kim J, Kim WJ, Choi YH, Yang SR, Hong SH. Diesel particle matter 2.5 induces epithelial-to-mesenchymal transition and upregulation of SARS-CoV-2 receptor during human pluripotent stem cell-derived alveolar gland development. Int J Environ Res Public Health. 2020;17(22):5502.

65. Tang PM, Nikolic-Paterson DJ, Lan HY. Macrophages: versatile players in renal inflammation and fibrosis. Nat Rev Nephrol. 2019;15(3):144–58.

66. Thery C, Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, Andriantsitohaina R, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles. 2018;7(1):153570.

67. Ye C, Li H, Bao M, Zhuo R, Jiang G, Wang W. Alveolar macrophage-derived exosomes modulate severity and outcome of acute lung injury. Aging (Albany NY). 2020;12(7):6120–8.

68. Huang R, Hao C, Wang D, Zhao Q, Li C, Wang C, et al. SPPI1 derived from silica-exposed macrophage exosomes triggers fibroblast transdifferentiation. Toxicol Appl Pharmacol. 2021;422:115559.

69. Guiot J, Cambier A, Boecka A, Henket M, Nivelles O, Gester F, et al. Macrophage-derived exosomes attenuate fibrosis in airway epithelial cells through delivery of anti-fibrotic miR-142-3p. Thorax. 2020;75(10):870–81.

70. Peggel DM, Gould SJ. Exosomes. Annu Rev Biochem. 2019;88:487–514.

71. Rayamajhi S, Nguyen TDT, Marasini R, Ayal S. Macrophage-derived exosomes-mimetic hybrid vesicles for tumor targeted drug delivery. Acta Biomater. 2019;94:482–94.

72. Iba S, Mager J, Breakefield XO, Wood MJ. Extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev Drug Discov. 2013;12(5):347–57.

73. Mathivanan S, Fahrner CJ, Reid GE, Simpson RJ. ExoCarta 2012: database of exosomal proteins, RNA and lipids. Nucleic Acids Res. 2012;40(D1):1241–1244.

74. Tkach M, Thery C. Communication by extracellular vesicles, where we are and where we need to go. Cell. 2016;164(6):1226–32.

75. Bovy N, Blomme B, Freers P, Dederen S, Nivelles O, Lion M, et al. Endothelial exosomes contribute to the antitumor response during breast cancer neoadjuvant chemotherapy via microRNA transfer. Oncotarget. 2015;6(12):10253–66.

76. Njock MS, Cheng HS, Dang LT, Nazari-Jahantigh M, Lau AC, Boudreau E, et al. Endothelial cells suppress monocytosis activation through secretion of extracellular vesicles containing anti-inflammatoriy microRNAs. Blood. 2015;125(20):3202–12.

77. Li C, Deng C, Zhou T, Hu J, Dai B, Yi Y, et al. MicroRNA-370 carried by M2 macrophage-derived exosomes alleviates asthma progression through inhibiting the FGFR1/MAPK/STAT1 axis. Int J Biol Sci. 2021;17(7):1795–807.

78. Osada-Oka M, Shotta M, Izumi Y, Nishiyama M, Tanaka M, Yamaguchi T, et al. Macrophage-derived exosomes induce inflammatory factors in endothelial cells under hypertensive conditions. Hypertens Res. 2017;40(4):353–60.

79. McDonald MK, Tian Y, Qureshi RA, Gormley M, Ertel A, Gao R, et al. Functional significance of macrophage-derived exosomes in inflammation and pain. Pain. 2014;155(8):1527–39.

80. Cui H, He Y, Chen S, Zhang D, Yu Y, Fan C. Macrophage-derived miRNA-containing exosomes induce peritendinous fibrosis after tendon injury through the miR-21-SnpSmad7 pathway. Mol Ther Nucleic Acids. 2019;14:114–30.

81. van den Berge M, Tasena H. Role of microRNAs and exosomes in disease modeling of hermansky-pudlak syndrome type 2 using human induced pluripotent stem cell-derived alveolar organoids. Stem Cell Rep. 2019;12(3):431–40.
